Formulation and evaluation of proniosomes containing lornoxicam
- 346 Downloads
Proniosomes are the new generation provesicular drug delivery system of non-ionic surfactant, lecithin and cholesterol which upon reconstitution get converted into niosomes. The objective of current study was to develop stable and sustain transdermal delivery system for lornoxicam. Lornoxicam-loaded topically applied proniosomal gel was formulated, optimized, and evaluated with the aim to deliver drug transdermally. Lornoxicam-loaded proniosomal gels were prepared that contained Lutrol F68 and lecithin as surfactants, cholesterol as a stabilizer, and minimal amount of ethanol and trace water. The resultant lornoxicam-loaded proniosomal gel were assessed for stability and the proniosomes-derived niosomes were characterized for morphology, size, zeta potential, and entrapment efficiency, which revealed that they were suitable for skin application. The coacervation phase separation technique was used in formulation of lornoxicam proniosomal gel and the gel was further assessed for in vitro permeation of lornoxicam through the freshly excised rat skin and the cumulative permeation amount of lornoxicam from proniosome, all exhibited significant increase as compared to 1.0 % lornoxicam-loaded pure gel. The optimized F5 batch had shown maximum entrapment efficiency up to 66.98 %. It has shown sustained drug release for more than 24 h. The skin permeability of proniosomal gel was found to be 59.73 %. The SEM and zeta potential studies showed formation of good and stable vesicles. Thus, proniosomes proved to have better potential for transdermal delivery of lornoxicam over conventional gel formulations.
KeywordsProniosomes Lornoxicam Lecithin Entrapment efficiency Gel
Compliance with ethical standards
Conflict of interest disclosure
The authors declare that there is no conflict of interest involved with this manuscript.
- 2.Chavan P, Jain B, Jain P. Proniosomes as drug carrier system for transdermal delivery of lornoxicam. World J Pharm Pharm Sci. 2012;1(1):393–404.Google Scholar
- 4.Li Q, Li Z, Zeng W, Ge S, Lu H, Wu C, et al. Proniosome-derived niosomes for tacrolimus topical ocular delivery: in vitro cornea permeation, ocular irritation, and in vivo anti-allograft rejection. Eur J Pharm Sci. 2014;62:115–23.Google Scholar
- 7.Kamboj S, Saini V, Bala S, Sharma G. Formulation and characterization of drug loaded niosomal gel for anti-inflammatory activity. Int Sch Sci Res Innov. 2013;2013(7):541–5.Google Scholar
- 8.Londhe VY, Thakkar V, Ranade SC. Topical delivery of lornoxicam: design, evaluation and effect of penetration enhancers. Indo American J Pharm Res. 2013;3:3174–81.Google Scholar
- 9.Kumarsingh V, Raj T, Kumarsingh P, Singh U, Singh AP, Kumar A. Design and development of a proniosomal transdermal drug delivery system of lornoxicam. Am J PharmTech Res. 2014;4:766–79.Google Scholar
- 10.El Maghraby GM, Ahmed AA, Osman MA. Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery. Saudi Pharm J. 2014;1–8.Google Scholar
- 16.Sezgin-Bayindir Z, Yuksel N. Investigation of formulation variables and excipient interaction on the production of niosomes. Am Assoc Pharm Scient. 2012;13:826–32.Google Scholar
- 24.Ahmed MO, Al-Badr AA. Profiles of drug substances, excipients, and related methodology. ISSN.36:206-219.Google Scholar
- 25.Li Q, Li Z, Zeng W, Ge S, Lu H, Wu C, et al. Proniosome-derived niosomes for tacrolimus topical ocular delivery. 2014;62:115–23Google Scholar